Therefore, we suggest that the decreased expression of TLR4 and CASP4/5 in both groups of BD patients may be associated with the protective role of mood-stabilizing treatment against inflammasome activation and further inflammatory response. The gene discussed is CASP4; the disease is Behcet disease.